Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

NCT00759291

Metabolic Syndrome

COMPLETED PHASE2/PHASE3

A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients

NCT04307511

Acute Coronary Syndrome Patients With Diabetes After PCI

RECRUITING PHASE4

Molecular Mechanisms and Carotid Atherosclerosis

NCT03962686

Diabetes Mellitus, Type 2 Atherosclerosis of Artery Atherosclerotic Plaque

COMPLETED

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

NCT02983214

Ischemic Stroke Peripheral Artery Disease Diabetes Mellitus, Type 2

COMPLETED PHASE4

Rosiglitazone Plaque Study

NCT00123227

Diabetes Mellitus, Type 2 Vascular Diseases Hypertension

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In type II diabetic patients with Coronary artery disease treated with clopidogrel and aspirin, the investigators plan to measure: i. maximum platelet aggregation to adenosine diphosphate (ADP) by Light Transmission Aggregometry (LTAmax), as a marker of on-clopidogrel treatment platelet reactivity ii. Malondialdehyde (MDA), as oxidative stress marker, Mitochondrial-derived peptide MOTS-c and b-amyloid. blood levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Clopidogrel Resistance Amyloid Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* type 2 diabetic patients with coronary artery disease, documented by coronary angiography,
* both per os or/and parenteral antidiabetic medications and double antiplatelet therapy (DAPT), constituted by a daily dose of 100 mg acetylsalicylic acid per os and a daily dose of 75 mg clopidogrel per os should be prescribed to the patients for at least one month before inclusion in the study

Exclusion Criteria

* abnormal renal function (creatinine\> 2.5 mg / dl),
* hepatic failure (bilirubin\> 2 mg / dl),
* active malignancy,
* patients treated with drugs that affect platelet function, besides aspirin 100 mg qd and clopidogrel 75 mg qd,
* patients with a history of hemorrhagic mood,
* patients with thrombocytopenia (PLTs \< 100x109 / L) and
* anemia (HCT \<28%).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ignatios Ikonomidis

Ignatios Ikonomidis,MD,PhD,FESC, Associate Professor of Cardiology, Director of Echocardiography and the Laboratory of Preventive Cardiology, 2nd Cardiology Department, National and Kapodistrian University of Athens

Responsibility Role PRINCIPAL_INVESTIGATOR